Business
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? Canada NewsWi...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\n The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n USA\n \n News Group\n \n\n\n News Commentary\n \n\n\n\n Issued on behalf of Oncolytics Biotech Inc.\n \n\n\n\n\n\n VANCOUVER, BC\n \n\n ,\n \n\n June 26, 2025\n \n\n /CNW/ --\n \n\n\n USA\n \n News Group\n \n\n\n News Commentary\n \n – With analysts forecasting the global oncology drug market to\n \n surpass\n \n US$900 billion\n \n\n by 2034, investor interest in cancer-focused biotechs is rapidly intensifying.\n \n\n ResearchAndMarkets\n \n\n and\n \n\n Vision Research Reports\n \n\n both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is\n \n facing potential setbacks\n \n . Budget proposals suggest\n \n National Cancer Institute (NCI)\n \n funding could be slashed by\n \n up to 40%,\n \n while\n \n Bloomberg\n \n\n highlights concerns\n \n around drug affordability and access. These headwinds are forcing a shift in expectations — placing the burden of innovation on the private sector, where companies like\n \n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC),\n \n Teva Pharmaceutical Industries Ltd.\n \n (NYSE: TEVA),\n \n Citius Oncology, Inc.\n \n (NASDAQ: CTOR),\n \n ADC Therapeutics SA\n \n (NYSE: ADCT), and\n \n OS Therapies Incorporated\n \n (NYSE-American: OSTX).\n \n\n\n\n\n\n\n\n The shift reflects more than a funding gap — it signals a structural realignment in how cancer breakthroughs may be brought to market. As public systems face pressure and timelines extend, nimble biotech firms are advancing targeted treatments, combination trials, and regulatory conversations once dominated by legacy institutions. Against this backdrop, market watchers see a pivotal window opening for investors willing to back the next wave of oncology innovation.\n \n\n\n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC) has entered a new chapter with the\n ...